For example, studies involving GLP-1 RAs have been shown to reduce major adverse cardiovascular events in patients with T2DM
This process is marked by the release of cytochrome c and Smac/DIABLO from the mitochondria into the cytoplasm, alongside a decrease in mitochondrial membrane potential (m), which signifies the opening of the mitochondrial permeability transition pore (PTP)
Technically, both are a type of growth hormone, but more accurately, they are what is known as GHRPs, or growth hormone releasing peptides, sometimes also referred to as human growth hormone-releasing hormones, (GHRH) or growth hormone releasing factors (GHRF)
Incomplete or inaccurate information affects both the quality of care and your safety
Ask for a timeline-based plan (stop date, alternative strategies, metabolic optimisation)
Comparing the three approaches One reason comparison articles often become misleading is because they assume every treatment is trying to accomplish the same thing